Anhui Anke BioTech Group Market Cap ($1.97 Billion)
Market Cap & Net Worth: Anhui Anke BioTech Group (300009)
Anhui Anke BioTech Group market cap. Anhui Anke BioTech Group (SHE:300009) has a market capitalization of $1.97 Billion (CN¥13.45 Billion) as of November 6, 2026. Listed on the SHE stock exchange, this China-based company holds position #6027 globally and #1114 in its home market, demonstrating a 2.94% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Anhui Anke BioTech Group's stock price CN¥8.05 by its total outstanding shares 1670700708 (1.67 Billion). Also see Anhui Anke BioTech Group cash conversion from operations for how efficiently the company converts equity into cash flow.
Anhui Anke BioTech Group Market Cap History (2015–2026)
Anhui Anke BioTech Group market cap history from 2015 to 2026. Data shows growth from $2.55 Billion to $1.97 Billion (2.84% CAGR). Check Anhui Anke BioTech Group stock quote for real-time trading data and today's change.
Index Memberships
Anhui Anke BioTech Group is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
ChiNext
CNT
|
$932.54 Billion | 0.21% | #82 of 100 |
Weight: Anhui Anke BioTech Group's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Anhui Anke BioTech Group Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Anhui Anke BioTech Group's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore 300009 year-over-year net asset growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.88x
Anhui Anke BioTech Group's market cap is 0.88 times its annual revenue
Latest Price to Earnings (P/E) Ratio
3.18x
Anhui Anke BioTech Group's market cap is 3.18 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.64 Billion | $849.22 Million | $197.30 Million | 1.93x | 8.31x |
| 2017 | $2.61 Billion | $1.10 Billion | $277.74 Million | 2.38x | 9.41x |
| 2018 | $1.90 Billion | $1.46 Billion | $263.17 Million | 1.30x | 7.20x |
| 2019 | $2.16 Billion | $1.71 Billion | $124.47 Million | 1.26x | 17.38x |
| 2020 | $2.76 Billion | $1.70 Billion | $358.96 Million | 1.62x | 7.68x |
| 2021 | $2.98 Billion | $2.17 Billion | $206.63 Million | 1.37x | 14.41x |
| 2022 | $2.18 Billion | $2.33 Billion | $703.26 Million | 0.93x | 3.09x |
| 2023 | $2.43 Billion | $2.87 Billion | $847.23 Million | 0.85x | 2.87x |
| 2024 | $2.11 Billion | $2.54 Billion | $706.95 Million | 0.83x | 2.99x |
| 2025 | $2.34 Billion | $2.65 Billion | $735.19 Million | 0.88x | 3.18x |
Competitor Companies of 300009 by Market Capitalization
Companies near Anhui Anke BioTech Group in the global market cap rankings as of November 6, 2026. Also see Anhui Anke BioTech Group (300009) total assets for a full breakdown of the balance sheet.
Key companies related to Anhui Anke BioTech Group by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #181 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #373 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #415 globally with a market cap of $67.74 Billion USD ( AU$95.74 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #503 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #181 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $549.04 |
| #373 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $930.67 |
| #415 | CSL Ltd | AU:CSL | $67.74 Billion | AU$197.34 |
| #503 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $258.38 |
Market Capitalization of Anhui Anke BioTech Group (2015–2026)
Market capitalization of Anhui Anke BioTech Group from 2015 to today. Between 2015 and today, Anhui Anke BioTech Group's market cap moved from $2.55 Billion to $ 1.97 Billion, with a yearly change of 2.84%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥1.97 Billion | -15.88% |
| 2025 | CN¥2.34 Billion | +10.76% |
| 2024 | CN¥2.11 Billion | -13.25% |
| 2023 | CN¥2.43 Billion | +11.92% |
| 2022 | CN¥2.18 Billion | -26.94% |
| 2021 | CN¥2.98 Billion | +8.05% |
| 2020 | CN¥2.76 Billion | +27.43% |
| 2019 | CN¥2.16 Billion | +14.11% |
| 2018 | CN¥1.90 Billion | -27.46% |
| 2017 | CN¥2.61 Billion | +59.29% |
| 2016 | CN¥1.64 Billion | -35.70% |
| 2015 | CN¥2.55 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of Anhui Anke BioTech Group was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.97 Billion USD |
| MoneyControl | $1.97 Billion USD |
| MarketWatch | $1.97 Billion USD |
| marketcap.company | $1.97 Billion USD |
| Reuters | $1.97 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Anhui Anke BioTech Group
Anhui Anke Biotechnology (Group) Co., Ltd. engages in the biopharmaceutical industry in China and internationally. It offers human growth hormone for injection under the Ansomone name; and recombinant human interferon alpha 2b lyophilized powder, liquid, and prefilled syringe for injection, as well as recombinant human interferon alpha 2b cream, eye drop, and suppository under the Anterferon name… Read more